Research graph
References from Pharmacologic Management of Type 2 Myocardial Infarction: An Underdefined Frontier. Local targets link to admitted publications; unresolved targets remain external evidence.
Fourth universal definition of myocardial infarction (2018)
10.1161/cir.0000000000000617 · 2018 · External reference
Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American heart Association
10.1161/cir.0000000000000670 · 2019 · External reference
Type 2 myocardial infarction
10.1016/j.jacc.2019.02.018 · 2019 · External reference
Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury
10.1161/circulationaha.119.040631 · 2019 · External reference
A systematic review on the triggers and clinical features of type 2 myocardial infarction
10.1002/clc.23230 · 2019 · External reference
The many faces of type 2 myocardial infarction
10.1016/j.jacc.2017.07.784 · 2017 · External reference
Coronary artery and cardiac disease in patients with type 2 myocardial infarction: a prospective cohort study
10.1161/circulationaha.121.058542 · 2022 · External reference
Coronary computed tomographic angiography with fractional flow reserve in patients with type 2 myocardial infarction
10.1016/j.jacc.2023.08.020 · 2023 · External reference
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines
10.1161/cir.0000000000001168 · 2023 · External reference
2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of Cardiology/American Heart Association Joint Committee on clinical practice Guidelines
10.1161/cir.0000000000001328 · 2025 · External reference
Antiplatelet therapy in cardiovascular disease: current status and future directions
10.1111/bcp.15221 · 2022 · External reference
Aspirin for primary prevention of cardiovascular diseases: “WALTZ” with the evidence
10.1007/s11886-022-01740-2 · 2022 · External reference
Meta-analysis comparing outcomes of type 2 myocardial infarction and type 1 myocardial infarction with a focus on dual antiplatelet therapy
10.1016/j.cjco.2020.02.005 · 2020 · External reference
Treatment with cardiovascular medications: prognosis in patients with myocardial injury
10.1161/jaha.120.017239 · 2021 · External reference
Adding insult to injury: are there treatments for myocardial injury and type 2 myocardial infarction?
10.1161/jaha.120.019796 · 2021 · External reference
Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis
10.1136/bmjopen-2021-055755 · 2022 · External reference
Characteristics and outcomes of type 2 myocardial infarction
10.1001/jamacardio.2022.0043 · 2022 · External reference
Management and outcome trends in type 2 myocardial infarction: an investigation from the SWEDEHEART registry
10.1038/s41598-023-34312-7 · 2023 · External reference
Sex differences in investigations and outcomes among patients with type 2 myocardial infarction
10.1136/heartjnl-2021-319118 · 2021 · External reference
Implications of misclassification of type 2 myocardial infarction on clinical outcomes
10.1016/j.carrev.2019.04.009 · 2020 · External reference
Type 2 myocardial infarction in general medical wards: clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction
10.1097/md.0000000000017404 · 2019 · External reference
Impact of type 2 myocardial infarction (MI) on hospital‐level MI outcomes: implications for quality and public reporting
10.1161/jaha.118.008661 · 2018 · External reference
Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury
10.1161/circulationaha.117.031806 · 2018 · External reference
Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice
10.2459/jcm.0000000000000504 · 2017 · External reference
Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis
10.1016/j.ijcard.2016.05.045 · 2016 · External reference
Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes
2016 · External reference
Type 2 myocardial infarction in clinical practice
10.1136/heartjnl-2014-306093 · 2015 · External reference
Sensitive troponin assay and the classification of myocardial infarction
10.1016/j.amjmed.2014.10.056 · 2015 · External reference
Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort
10.1016/j.amjmed.2013.12.020 · 2014 · External reference
Type-II myocardial infarction--patient characteristics, management and outcomes
10.1371/journal.pone.0084285 · 2014 · External reference
Mortality in type 1 vs. type 2 myocardial infarction
10.1093/eurheartj/eht308.p1331 · 2013 · External reference
Zontivity (Vorapaxar), first-in-class PAR-1 antagonist, receives FDA approval for risk reduction of heart attack, stroke, and cardiovascular death
2015 · External reference
Universal classification system type of incident myocardial infarction in patients with stable atherosclerosis: observations from thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2°P)-TIMI 50
10.1161/jaha.116.003237 · 2016 · External reference
Meta-regression analysis of the impact of medical therapy on long-term mortality in type 2 myocardial infarction
10.1016/j.amjcard.2021.10.044 · 2022 · External reference
Clinical outcomes associated with type II myocardial infarction caused by bleeding
10.1016/j.ahj.2023.05.008 · 2023 · External reference
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
10.1016/s0140-6736(18)30832-8 · 2018 · External reference
Anticoagulation in type 2 myocardial infarctions: lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial
10.1016/j.conctc.2023.101143 · 2023 · External reference
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
10.1093/eurheartj/ehz299 · 2019 · External reference
Impact of β-blockers on mortality in critically ill patients with type 2 myocardial infarction: insights from a retrospective cohort study
10.3389/fcvm.2025.1531711 · 2025 · External reference
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
10.1161/01.cir.100.15.1602 · 1999 · External reference
Role of statins in coronary artery disease
10.4068/cmj.2013.49.1.1 · 2013 · External reference
Effect of statins on atherosclerotic plaque
10.1016/j.tcm.2019.01.001 · 2019 · External reference
2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2024.11.009 · 2025 · External reference
The evolution of β-Blockers in coronary artery disease and heart failure (part 1/5)
10.1016/j.jacc.2019.04.067 · 2019 · External reference
Smritigandha. Role of β-blockers in preventing heart failure and major adverse cardiac events post myocardial infarction
10.2174/1573403x19666230111143901 · 2023 · External reference
Classification of myocardial infarction: frequency and features of type 2 myocardial infarction
10.1016/j.amjmed.2013.02.029 · 2013 · External reference
Type 2 myocardial infarction: challenges in diagnosis and treatment
10.1093/eurheartj/ehae803 · 2025 · External reference
Cardiovascular risk across myocardial injury and infarction categories using the universal definition: an individual patient-level data meta-analysis
10.1016/j.jacc.2025.11.043 · 2026 · External reference
